EMA
The European Medicines Agency (EMA) is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union. It began operating in 1995.
Business & Industry
- Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate
- AstraZeneca advances mass global rollout of COVID-19 vaccine through COVAX
- Abbott researchers find rare group of people with controlled HIV who could be a key to unlocking cure
- Pfizer and BioNTech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants
- Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
Research & Development
- New evidence COVID-19 antibodies, vaccines less effective against variants
- Vaccine development software shows promise in influenza effort, could help defeat coronavirus
- Researchers discover SARS-CoV-2 inhibitors
- Nanoparticle-delivered COVID-19 vaccine candidate shows promise in preclinical studies
- First COVID-19 COVAX vaccine doses administered in Africa
- Assessing a compound's activity, not just its structure, could accelerate drug discovery
- Arthritis drugs may reduce mortality and time in ICU for sickest COVID patients
Conferences & Events
- Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
- COVID-19 vaccine innovation could dramatically speed up worldwide production
Regulatory Affairs
- FDA issues Emergency Use Authorization for third COVID-19 vaccine
- FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19
- EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
- FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
- Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application